How Drug Discovery Is Tackling Global Health Challenges

The antimicrobial resistance (AMR) threat is no longer theoretical; the 2014 O'Neill report warned that by 2050 the global economic burden could reach $100 trillion and cause ten million deaths annually. Professor Janet Hemingway emphasizes that small‑and medium‑sized enterprises now account for three‑quarters of antibacterial R&D, yet they struggle to fund costly phase‑I and phase‑II trials. Initiatives such as the ICON Infection Innovation Consortium connect academia, industry, and the NHS, delivering 36 products since 2020, including vaccines entering human‑challenge studies in Malawi. Without larger pharmaceutical players and stronger pull incentives, promising discoveries risk stalling before reaching patients.

Recent breakthroughs show how technology can revive the antibiotic pipeline. Researchers at Roche and Harvard identified a novel class of compounds—osorabolpin—that dismantles the LPT‑B2‑FGC complex of carbapenem‑resistant Acinetobacter baumannii, while MIT scientists used deep‑learning models to discover candidates active against methicillin‑resistant Staphylococcus aureus. These discoveries illustrate AI’s capacity to spot hidden chemical space, yet transitioning from mouse models to human trials remains a financial choke point. The UK’s subscription‑based AMR Pilot, now offering up to £20 million (≈ $25 million) per year for high‑value antibiotics, demonstrates a pull‑mechanism, but global markets must adopt similar schemes to entice big‑pharma participation.

The mRNA revolution, sparked by COVID‑19 vaccines, has expanded into therapeutics beyond infectious disease. Valued at $3.4 billion in 2018, the market now exceeds $40 billion, driven by companies such as Pfizer, Moderna and emerging biotech firms. Early 2024 saw the first patient dosed in an mRNA‑4359 cancer trial, testing combinations with checkpoint inhibitor pembrolizumab, while University College London and Moderna demonstrated a weekly lipid‑nanoparticle mRNA therapy that prolonged survival in a mouse model of a rare liver disorder. With over 190 organizations developing 310 mRNA candidates, experts predict mRNA will dominate prophylactic vaccines and become a core platform for precision medicines within the next decade.